Background <p>Leptomeningeal metastasis (LM) is a fatal complication of advanced cancer with limited therapeutic options and poor prognosis. Immune checkpoint inhibitors (ICIs) have shown promise in systemic disease, but intrathecal ICIs efficacy and immunological impact in LM remain unclear. Cerebrospinal fluid (CSF) proteomics may provide a unique window into the CNS immune microenvironment and enable response prediction.</p> Methods <p>We enrolled…
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
Journal for ImmunoTherapy of Cancer | | Wang, L., Yang, G., Lei, H., Zhang, Y., Li, B., Liu, M., Huang, Y., Chen, X., Tai, P., Pan, Z.
Topics: immunotherapy, targeted-therapy, research
Read the full article at Journal for ImmunoTherapy of Cancer